Suramin: a novel antineoplastic agent with multiple potential mechanisms of action.
about
Directed molecular screening for RecA ATPase inhibitorsStructures to complement the archaeo-eukaryotic primases catalytic cycle description: What's next?Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small moleculeApplication of a novel microtitre plate-based assay for the discovery of new inhibitors of DNA gyrase and DNA topoisomerase VISuramin inhibits Hsp104 ATPase and disaggregase activityPharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.Suramin inhibits renal fibrosis in chronic kidney disease.Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathySuramin inhibits wound healing following filtering procedures for glaucoma.TNF superfamily protein-protein interactions: feasibility of small- molecule modulationDiscovery of GSK2795039, a Novel Small Molecule NADPH Oxidase 2 Inhibitor.Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suraminPhase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanesTargeting vasculature in urologic tumors: mechanistic and therapeutic significance.Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells.Suramin inhibits cullin-RING E3 ubiquitin ligases.The effect of suramin on inhibiting fibroblast proliferation and preventing epidural fibrosis after laminectomy in ratsA combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cellsPhosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity.Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides.Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial.Co-existence of P2Y-and PPADS-insensitive P2U-purinoceptors in endothelial cells from adrenal medulla
P2860
Q24684082-5A61C492-D7B8-49F6-BE88-2CC71110BE7FQ26828801-5BB4D704-EE93-4DCF-B5FF-6A1D51A7A512Q28368422-88200717-6C8D-4F77-8F15-0A7C5D57530EQ28482295-227A4EE6-338D-4C69-B1CF-95BFE78AB879Q28486816-27607572-0A98-4270-A6EA-DC0D084DFF66Q28543672-3936B457-2EDB-42EF-BC8B-5B31126BA095Q34871781-3F199D6F-8559-42BA-969C-EF2211EA668BQ35012404-8FFBF640-3E27-4D0B-B4C5-59141E05B71EQ35188138-2D1AAD14-32FC-47B9-B377-CC8D9FD40F0AQ35306077-36A93DD6-C945-488A-B194-83820748FBD3Q35534271-A68085BC-42A8-41FD-8869-7EA246F86DD4Q35984159-0C072CA4-F99F-46DF-86E4-2295D97ADD73Q36081413-455EF3A9-A86A-466F-A5DC-EAFAE3B90FF5Q36304316-D7D9743C-630F-44FD-9C3F-B9D7E034BC98Q36508627-16232567-891E-417F-86B1-FCFC5146D1D0Q36563976-AB8EC6CD-5A12-4A48-92C7-33F3A24E7DA6Q36802367-F1650B74-E09F-4E21-94C5-DCABE36C6612Q37302353-956B95CA-11D5-47AD-9871-DA0C0356588CQ37696774-863532AB-8BE5-42DC-8D00-325AD18BD7DAQ38290188-1CF2EAF5-985E-4324-92FF-190A642EBBC5Q38361683-58A78A37-DDD3-452F-8FB5-8BA25B08D732Q40962449-22411815-DA6A-4E4F-895F-C1B39995C191Q42527472-E243C493-D35E-4CC4-B379-4453D0647D85
P2860
Suramin: a novel antineoplastic agent with multiple potential mechanisms of action.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Suramin: a novel antineoplastic agent with multiple potential mechanisms of action.
@en
type
label
Suramin: a novel antineoplastic agent with multiple potential mechanisms of action.
@en
prefLabel
Suramin: a novel antineoplastic agent with multiple potential mechanisms of action.
@en
P1433
P1476
Suramin: a novel antineoplastic agent with multiple potential mechanisms of action.
@en
P2093
P304
P407
P433
P577
1993-05-01T00:00:00Z